Navigation Links
Pure MHC and Catalent Sign RL21 Anti-Cancer Development Deal

Somerset, NJ, and Austin, TX (PRWEB) November 21, 2013

Pure MHC, LLC, a provider of MHC-based diagnostics and therapeutics, and Catalent Pharma Solutions, the global leader in drug development solutions and advanced delivery technologies for pharmaceutical, biologic and consumer health products, today announced the signing of a product development agreement. Under the terms of the agreement, Catalent will develop a humanized version of Pure MHC’s proprietary RL21A antibody and engineer a cell line to express the antibody using Catalent’s GPEx® technology. Catalent will subsequently produce purified monoclonal antibodies to support Pure MHC’s preclinical development in preparation for clinical trials with humanized RL21A for the treatment of cancer. GPEx technology is used to generate mammalian cells with high yields and stability, helping to speed drugs to clinic.

“We are confident that our partnership with Catalent will result in the development of the enhanced antibodies necessary to help get RL21A into the clinic more quickly,” said Thomas Harlan, CEO of Pure MHC, “Our ultimate goal for this technology is to one day provide cancer patients with a treatment option that is safer and more effective than those available today.”

“We are delighted to again demonstrate how GPEx technology, together with Catalent’s development and manufacturing expertise, can support development of novel therapies and enable companies such as Pure MHC to validate their unique target screening methodology,” said Jonathan Arnold, VP, General Manager of Catalent’s Advanced Delivery Technologies business.

Pure MHC has developed a suite of MHC/ligand targets that recognize cancerous cells in addition to producing monoclonal antibodies for these distinct MHC/ligand cancer targets. Antibodies such as RL21A distinguish primary cancers from healthy tissue and, in animal models, have been shown to arrest tumor development.

About Catalent
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing worldwide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit

More products. Better treatments. Reliably supplied.™

About Pure MHC
Pure MHC is an immunology company focused on MHC-based diagnostics and therapeutics that was formed from innovative technologies developed in two Emergent Technologies portfolio companies, Pure Protein, LLC and Receptor Logic, LLC, to provide a novel solution for the treatment of infectious diseases and cancers. Pure Protein, founded in 1999 and led by William Hildebrand, PhD, has technology to manufacture soluble HLA proteins that are used in a proprietary method of novel immunogenic epitope discovery and validation. Receptor Logic, founded in 2003 and led by Jon Weidanz, PhD, has proprietary technology for generating T-cell Receptor mimics from novel epitopes defined by Pure Protein. For more information, visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Catalent Creates New Advanced Delivery Technologies Business Unit
2. Catalent’s Clinical Trial Supply Facility in Shanghai, China Opens for Business
3. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
4. 1960s-era anti-cancer drug points to treatments for Lou Gehrigs disease
5. Specialized MRI scans assess value of anti-cancer chemotherapy long before tumors shown to shrink
6. First trial in humans of minicells: A completely new way of delivering anti-cancer drugs
7. Development of the first way to make large amounts of promising anti-cancer substance
8. Progress after recent breakthrough which opened new chapter in anti-cancer cell therapies
9. Overcoming resistance to anti-cancer drugs by targeting cell powerhouses
10. Anti-cancer drug viewed as possible Alzheimers treatment doesnt work in UF study
11. New understanding of why anti-cancer therapy stops working at a specific stage
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has focused on providing comprehensive solutions involving adult stem cell therapies to patients ... officially deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are ...
(Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
(Date:11/24/2015)... ... November 24, 2015 , ... New patients who wish ... referral for dental implants at her Mississauga, ON practice. Dr. Williams has ... the placement of dental implants. , Missing teeth can lead to a variety ...
(Date:11/24/2015)... FRANCISCO, CA (PRWEB) , ... November 24, 2015 ... ... half-cup sizes, has launched their Black Friday sale a week early, offering 40% ... continues to transform the intimate apparel industry through both mobile fit technology and ...
(Date:11/24/2015)... ... November 24, 2015 , ... DMG Productions announced that they will feature ... quarter 2016 via Discovery Channel. Dates and show times TBA. , Aphria, Inc., is ... the business of producing and supplying medical marijuana pursuant to the Marijuana for Medical ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... November 25, 2015 ... addition of the  "Global Drug Device ... to their offering.  --> ... of the  "Global Drug Device Combination ... their offering.  --> Research ...
(Date:11/24/2015)... 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" or ... R&D capability and technology platform company serving the pharmaceutical, ... China and the United ... general meeting of shareholders held today, the Company,s shareholders ... approve the previously announced agreement and plan of merger ...
(Date:11/24/2015)... CARLOS, Calif. , Nov. 24, 2015 ... a leader in non-invasive genetic testing and ... announced that it will present at the ... in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew ... the Company,s financial results, business activities and ...
Breaking Medicine Technology: